Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TB-403||RG7334|RO5323441||TB-403 (RO5323441) is an antibody directed against Placental Growth Factor (PLGF), which inhibits binding of PLGF to VEGFR1, potentially resulting in decreased tumor growth (PMID: 22333707, PMID: 25665807).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||TB-403||Phase I||Actionable||In a Phase I trial, TB-403 (RO5323441) demonstrated safety and some preliminary evidence of activity in patients with advanced solid tumors (PMID: 22333707).||22333707|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02748135||Phase Ib/II||TB-403||A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma||Completed||USA||0|